Key takeaways:
If you have Type 2 diabetes, you may need to take more than one medication to balance your blood sugar. For many people, their treatment plan includes metformin.
There are several combination products that contain metformin plus another diabetes medication. Switching to one may reduce the number of pills you take every day.
Many combination diabetes medications are only available as brand-name medications. GoodRx can help you navigate copay savings cards and patient assistance programs to help make them more affordable.
If you’re living with Type 2 diabetes, metformin is often one of the first medications you’re prescribed. It helps reduce the amount of sugar (glucose) your body absorbs and makes. And it also helps your body use insulin more effectively. But sometimes metformin isn’t enough.
Your healthcare provider may decide to prescribe another oral diabetes medication along with metformin. But all of these pills and prescription costs can start to add up. If this sounds like your situation, combination pills may be an option to consider.
Many combination diabetes pills contain metformin with another medication. For some people, these products mean fewer daily pills and lower costs. But what should you know before making the switch? Let’s review a few popular combinations.
Save on popular GLP-1 Agonists
Take control of your health. With GoodRx, you may be eligible to save even more on popular treatments.
Janumet (sitagliptin/metformin) has been available in the U.S. for at least 15 years. It combines sitagliptin (Januvia) and metformin into a twice-daily tablet. Janumet XR is the extended-release (ER) version that you take once a day.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, or simply a “gliptin” medication. It works by blocking the hormone DPP-4, which helps your pancreas release insulin. It also prevents your liver from making extra glucose. This combined action works to help balance your blood glucose.
If you aren’t able to achieve your blood sugar goals on metformin alone, your healthcare provider may add on a DPP-4 inhibitor. These medications can be a good option for people who want to minimize the risk of low blood sugar (hypoglycemia).
Janumet and Janumet XR are only available as brand-name medications. The same is true for Januvia. Lower-cost generics for all three medications may be available mid-2026.
Until then, you may be able to save on your Janumet or Janumet XR prescription with a copay savings card from the manufacturer. If you’re eligible, you could pay as little as $5 for your prescription. Patient assistance programs are also available that provide the medications free of charge for eligible people who are uninsured or underinsured.
Jentadueto (linagliptin/metformin) is similar to Janumet. It combines a DPP-4 inhibitor with metformin. The DPP-4 inhibitor in this combination is linagliptin (Tradjenta). It’s also taken twice daily. The ER version, Jentadueto XR, is taken once daily.
There doesn’t appear to be significant differences between how well Janumet and Jentadueto work. So, your healthcare provider will decide which is best for you based on availability, cost, and other factors.
Jentadueto and Jentadueto XR are both brand-name medications. It’ll likely be several years before generic versions are available. Tradjenta is also only available as a brand-name product.
There are a few ways to save on Jentadueto and Jentadueto XR in the meantime. For example, you can pay as little as $10 for your prescription with a copay savings card. A patient assistance program is also available.
Our final DPP-4 inhibitor combination is Kombiglyze XR (saxagliptin/metformin). It combines saxagliptin (Onglyza) with metformin in a once-daily ER tablet. Kombiglyze XR works the same way as Janumet and Jentadueto.
Your healthcare provider will determine if Kombiglyze XR is a good option for you. One factor they may consider is drug interactions. Certain medications can increase the amount of saxagliptin in your blood. When taken together, these combinations require a lower Kombiglyze XR dose. Other DPP-4 inhibitors don’t have these same interactions.
Kombiglyze XR is only available as a brand-name medication. But a generic version may hit the market as soon as 2023. This is also the case for Onglyza.
Before a generic is available, there are other ways to save on Kombiglyze XR. For example, you could pay as little as $0 per month with a copay savings card. Or you may qualify for the medication’s patient assistance program.
Synjardy (empagliflozin/metformin) is a combination of empagliflozin (Jardiance) and metformin. It’s typically taken twice daily. The ER version, called Synjardy XR, is taken once daily.
Empagliflozin blocks a protein called sodium-glucose cotransporter 2 (SGLT2) in the kidneys. This results in your kidneys removing excess glucose and sodium through your urine. Empagliflozin and similar medications are referred to as SGLT2 inhibitors or “flozin” medications.
Beyond controlling diabetes, SGLT2 inhibitors have other uses. Empagliflozin, in particular, also has heart-related benefits. If you have heart disease, your healthcare provider may add empagliflozin to help lower your risk of death from heart disease.
Both Synjardy and Synjardy XR are only available as brand-name medications. Generic versions of both medications have been approved, but it’ll likely be a few years before they’re available. Jardiance also doesn’t have a generic version.
If you’re eligible, you could pay as little as $10 for your Synjardy or Synjardy XR prescription with a copay savings card. Patient assistance programs are also available.
Next, we have Xigduo XR (dapagliflozin/metformin). It combines dapagliflozin (Farxiga) with metformin in a once-daily ER tablet.
Like empagliflozin, dapagliflozin is an SGLT2 inhibitor. But it has different heart-related benefits, so it may be preferred in certain situations. For example, if you have heart disease (or heart disease risk factors), it can help lower the risk of hospitalization from heart failure. And if you have kidney problems, dapagliflozin can help them from getting worse.
Xigduo XR is only available as a brand-name medication. And we still have several years before a generic version will be available. Farxiga doesn’t have a generic version, either.
Xigduo XR’s manufacturer offers a copay savings card that can make your prescription more affordable. If you’re eligible, you could pay as little as $0 for your prescription. The same is true if you qualify for their patient assistance program.
Invokamet (canagliflozin/metformin) is another SGLT2 inhibitor combined with metformin in a twice-daily tablet. In this case, canagliflozin (Invokana) is the SGLT2 inhibitor. It’s also available as a once-daily ER product called Invokamet XR.
Like the other SGLT2 inhibitors we’ve covered, canagliflozin has additional benefits. If you have heart disease, your healthcare provider may add it to help lower your risk of heart attack and stroke. Like dapagliflozin, canagliflozin also has kidney-related benefits.
Invokamet and Invokamet XR are only available as brand-name medications. This is also the case for Invokana. It may be several years before we’ll see generic versions available.
If you’re eligible, you could pay as little as $0 for your Invokana or Invokana XR prescription with a copay savings card. A patient assistance program is also available.
The last combination pill we’ll review is Segluromet (ertugliflozin metformin). It combines the SGLT2 inhibitor ertugliflozin (Steglatro) with metformin. The combination is similar to Synjardy, Xigduo, and Invokamet. It’s typically taken twice daily.
Ertugliflozin is the newest SGLT2 inhibitor to be approved. It has been studied for potential heart-related benefits, but isn’t approved for additional uses yet.
Segluromet is only available as a brand-name medication. The same is true for Steglatro. Since it has been approved more recently, we won’t see a generic for a while.
Segluromet’s manufacturer has a copay savings card that can help you save on your prescription. If eligible, you could pay as little as $0 per prescription.
Combination diabetes pills aren’t right for everyone. But they may be a good fit for you based on a few factors:
Convenience. You may be able to cut down the number of daily pills you’re taking with a combination product. Several products also have a once-daily dosing option.
Adherence. Fewer pills may make it easier to stick with your treatment plan.
Cost. You may be able to save on your prescription costs by paying only one copay, especially if you’re eligible for a copay savings card.
However, you don’t have as much dosing flexibility with combination products. That’s because each pill contains fixed doses of each medication. If you’re not stable on each medication separately, it may be more difficult to switch to a combination product.
If you think you may benefit from a combination diabetes medication, speak with your healthcare provider. They can determine if it’s an option for you.
If you’re taking metformin with another oral Type 2 diabetes medication, a combination pill may be an option. Making the switch could reduce the number of pills you take or help save you money.
The combination diabetes medications listed above are only available as brand-name versions. Manufacturer copay savings cards and patient assistance programs can help make them more affordable. Lower-cost generic versions may be available in the coming years.
AstraZeneca Pharmaceuticals LP. (2017). Kombiglyze [highlights of prescribing information].
AstraZeneca Pharmaceuticals LP. (2022). Xigduo XR [highlights of prescribing information].
Bell, D. S. H. (2013). Combine and conquer: Advantages and disadvantages of fixed-dose combination therapy. Diabetes, Obesity and Metabolism.
Blonde, L., et al. (2022). American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a diabetes mellitus comprehensive care plan—2022 update. Endocrine Practice.
Bloomberg Law. (2017). AstraZeneca diabetes drugs won’t face generics until 2023.
Boehringer Ingelheim Pharmaceuticals, Inc. (2022). Synjardy [highlights of prescribing information].
Bryant Ranch Prepack. (2022). Invokamet [package insert].
Cosentino, F., et al. (2020). Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: Results of the VERTIS CV trial. Circulation.
Keshavarz, K., et al. (2017). Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: A network meta-analysis of randomized clinical trials. Daru.
Kovacich, N., et al. (2018). Ertugliflozin (steglatro): A new option for SGLT2 inhibition. Pharmacy and Therapeutics.
Kurtz, S. (2020). ANDA tentative approval [208454]. U.S. Food and Drug Administration.
Kurtz, S. (2022). ANDA Tentative Approval [211583]. U.S. Food and Drug Administration.
Maideen, N. M. P. (2019). Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World Journal of Meta-Analysis.
Merck & Co., Inc. (2022). Janumet [highlights of prescribing information].
Merck Sharp and Dohme LLC. (2022). Segluromet [package insert].
Merck. (n.d.). Activate the card.
Merck. (2022). U.S. District Court rules in favor of Merck in sitagliptin phosphate patent lawsuit.
Press Trust of India. (2020). Alembic Pharma gets tentative nod from USFDA for diabetes management drug. Business Standard.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2022). Drugs@FDA: FDA-approved drugs [212198].
Venkata, S., et al. (2022). Dipeptidyl peptidase IV (DPP IV) inhibitors. StatPearls.